(ANSA) - NEW YORK, JAN 06 - The US Food and Drug Administration authorizes Eisai's long-awaited Alzheimer's drug eBiogen.
In the studies performed, Leqembi has shown promising results for the treatment of the disease, which affects about 6.5 million Americans, with an evident slowdown of the disease.
The FDA has granted the drug the expedited green light and this means that the two companies will have to conduct other studies.
(HANDLE).